Jyothy Labs was talking up Pril while quietly killing it
Management told investors in May they'd keep investing in Pril. By June 1, manufacturing stopped. Arbitration at SIAC has begun.
— 1 earlier story on Jyothy Labs Ltd. →What's new
- Pril and Fa manufacturing ceased June 1, earlier than signaled publicly.
- Management had said in May they'd continue investing in Pril while exit talks were already underway.
- Arbitration initiated at Singapore International Arbitration Centre (SIAC) over exit terms.
- FY27 called a transition year with expected margin softness.
Why this matters
A 15-year partnership ends with a credibility gap: executives told the market one thing while negotiating the opposite. Pril's exit removes 7-8% of revenue and forces a costly pivot to Exo, with margins under pressure in the transition year.
What we're watching
- SIAC arbitration outcome on brand valuation and exit compensation.
- Exo's market share uptake against the relaunched brand at parity pricing.
- Margins in Q1FY27 – first full quarter without Pril.
The full read
Jyothy Labs' 15-year run with Henkel ended not with a bang but with a contradiction. On June 1, production of Pril and Fa stopped, removing 7-8% of revenue. Yet just weeks earlier, management told investors it would keep spending on the brands. The disconnect is hard to ignore. Arbitration at SIAC will decide exit terms and brand value, but the immediate impact is on credibility. FY27 is now a transition year: margins will soften as Jyothy pivots to Exo, relaunched at parity pricing. The ₹225-240 crore Pril contributed isn't replaceable overnight. The open question is whether the pivot works fast enough to avoid a second straight year of profit decline; PAT already fell 11.5% on a trailing basis.
Questions answered
- When did Jyothy Labs stop making Pril and Fa?
- Manufacturing ended on June 1, 2026, despite management stating in May that they would continue investing in Pril. The license agreements with Henkel expired on May 31.
- How much revenue did Pril contribute?
- Pril represented roughly 7-8% of consolidated revenue, or about ₹225-240 crore annually. This is a material chunk for a company with trailing 12-month sales around ₹2,700 crore.
- What is the status of legal proceedings with Henkel?
- Jyothy has initiated arbitration at the Singapore International Arbitration Centre (SIAC) to assert its contractual rights on exit terms and brand valuation. The company had previously sued Henkel over the license expiry.
- How will FY27 be affected?
- Management explicitly called FY27 a transition year with expected margin softness as the company pivots to the Exo brand, which has been relaunched at market-leader parity pricing. Pril's absence will weigh on both revenue and profitability.
- What did management say publicly about Pril during the exit talks?
- In May 2026, executives stated they would continue investing in both Pril and Exo. However, the concall revealed they had been negotiating the exit for months, creating a credibility gap.
- What is the scale of the Exo brand relaunch?
- Exo has been relaunched at market-leader parity pricing, suggesting an aggressive push to replace Pril's shelf space. Success will depend on consumer uptake and distribution reach.
Jyothy Labs Ltd.
Latest quarter · Mar 2025
Strength & growth
Story so far
All notes on JYOTHYLAB →- 18 Jun 2026 · 6:05 PM IST Jyothy Labs was talking up Pril while quietly killing it
- 21d ago Jyothy Labs sues Henkel over Pril and Fa brand license expiry